Trader Aytu BioScience, Inc. - AYTU CFD
Ajouter aux favoris- Résumé
- Données historiques
- Événements
- Compte de résultat
- Bilan
- Flux de trésorerie
- Capital
Conditions de trading
| Écart | 0.098 | ||||||||
|
Frais de position longue en overnight
Long position overnight fee
Aller vers la plateforme | -0.025457% | ||||||||
|
Frais de position courte en overnight
Short position overnight fee
Aller vers la plateforme | 0.003235% | ||||||||
| Durée des frais en overnight | 21:00 (UTC) | ||||||||
| Quantité minimale négociée | 0.01 | ||||||||
| Devise | USD | ||||||||
| Marge | 20% | ||||||||
| Bourse | United States of America | ||||||||
| Commission sur la négociation | 0% |
*Information provided by Capital.com
Aytu Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Chiffres clés
| Fermeture précédente* | 1.647 |
| Ouvert* | 1.597 |
| Variation sur 1 an* | 193.03% |
| Fourchette du jour* | 1.597 - 1.736 |
| Fourchette sur 52 semaines | 1.40-16.19 |
| Volume moyen (10 jours) | 55.32K |
| Volume moyen (3 mois) | 1.68M |
| Capitalisation boursière | 6.50M |
| Ratio C/B | -100.00K |
| Actions en circulation | 3.78M |
| Revenu | 104.12M |
| EPS | -206.58 |
| Dividende (rendement en %) | N/A |
| Bêta | -0.38 |
| Prochaine date de publication des résultats | Sep 25, 2023 |
Toutes les données sont fournies par Refinitiv, à l'exception des données marquées d'un astérisque, qui sont des *données fournies par Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Clôture | Change | Change (%) | Ouverture | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 1.736 | 0.139 | 8.70% | 1.597 | 1.736 | 1.587 |
| Jun 1, 2023 | 1.647 | 0.060 | 3.78% | 1.587 | 1.667 | 1.568 |
| May 31, 2023 | 1.618 | -0.038 | -2.29% | 1.656 | 1.657 | 1.568 |
| May 30, 2023 | 1.618 | -0.078 | -4.60% | 1.696 | 1.697 | 1.587 |
| May 26, 2023 | 1.627 | 0.000 | 0.00% | 1.627 | 1.805 | 1.617 |
| May 25, 2023 | 1.618 | -0.147 | -8.33% | 1.765 | 1.766 | 1.558 |
| May 24, 2023 | 1.746 | -0.029 | -1.63% | 1.775 | 1.815 | 1.696 |
| May 23, 2023 | 1.765 | -0.009 | -0.51% | 1.774 | 1.904 | 1.765 |
| May 22, 2023 | 1.874 | 0.020 | 1.08% | 1.854 | 1.934 | 1.824 |
| May 19, 2023 | 1.844 | 0.020 | 1.10% | 1.824 | 1.934 | 1.795 |
| May 18, 2023 | 1.835 | 0.020 | 1.10% | 1.815 | 1.854 | 1.775 |
| May 17, 2023 | 1.736 | 0.090 | 5.47% | 1.646 | 1.746 | 1.607 |
| May 16, 2023 | 1.677 | 0.001 | 0.06% | 1.676 | 1.795 | 1.666 |
| May 15, 2023 | 1.726 | 0.011 | 0.64% | 1.715 | 1.805 | 1.697 |
| May 12, 2023 | 1.776 | -0.246 | -12.17% | 2.022 | 2.022 | 1.726 |
| May 11, 2023 | 2.022 | -0.010 | -0.49% | 2.032 | 2.151 | 1.913 |
| May 10, 2023 | 2.002 | 0.060 | 3.09% | 1.942 | 2.092 | 1.804 |
| May 9, 2023 | 1.953 | 0.326 | 20.04% | 1.627 | 2.052 | 1.577 |
| May 8, 2023 | 1.667 | 0.208 | 14.26% | 1.459 | 1.697 | 1.459 |
| May 5, 2023 | 1.480 | 0.041 | 2.85% | 1.439 | 1.519 | 1.341 |
Aytu BioScience, Inc. Events
| Heure (UTC) (UTC) | Pays | Événement |
|---|---|---|
| Monday, September 25, 2023 | ||
| Heure (UTC) (UTC) 20:00 | Pays US
| Événement Q4 2023 Aytu Biopharma Inc Earnings Release Q4 2023 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 13, 2023 | ||
| Heure (UTC) (UTC) 21:00 | Pays US
| Événement Q1 2024 Aytu Biopharma Inc Earnings Release Q1 2024 Aytu Biopharma Inc Earnings ReleaseForecast -Previous - |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu total | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Revenu | 96.669 | 65.632 | 27.6321 | 7.32036 | 3.66012 |
| Coût des recettes, total | 44.386 | 36.432 | 7.55303 | 2.20204 | 2.05054 |
| Résultat brut | 52.283 | 29.2 | 20.0791 | 5.11832 | 1.60958 |
| Total des frais d'exploitation | 208.061 | 126.071 | 38.6481 | 33.9975 | 17.0825 |
| Total des frais de vente/Généraux/Admin | 69.88 | 55.808 | 34.8024 | 19.2396 | 17.7325 |
| Recherche et développement | 14.439 | 5.623 | 1.72142 | 0.58907 | 0.1676 |
| Depreciation / Amortization | 4.067 | 6.009 | 4.49047 | 2.13626 | 1.55371 |
| Charges (revenus) inhabituelles | 75.289 | 22.199 | -9.91925 | 9.83055 | -4.42185 |
| Produits d'exploitation | -111.392 | -60.439 | -11.016 | -26.6772 | -13.4224 |
| Produits (charges) d'intérêts, nets Hors exploitation | -0.862 | -2.05 | -2.60466 | -0.45472 | 3.2345 |
| Résultat net avant impôts | -110.283 | -58.03 | -13.6207 | -27.1319 | -10.1879 |
| Résultat net après impôts | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Résultat net avant éléments extra | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Résultat net | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Résultat net dilué | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Moyenne pondérée des actions diluées | 0.07349 | 0.83733 | 0.22596 | 0.03897 | 0.00333 |
| BPA dilué hors éléments extraordinaires | -1499.08 | -69.6126 | -60.2791 | -696.182 | -3061.23 |
| Dividends per Share - Common Stock Primary Issue | |||||
| BPA dilué normalisé | -833.202 | -52.3801 | -104.177 | -443.938 | -4389.91 |
| Total des éléments extraordinaires | 0 | ||||
| Autres, nets | 1.971 | 4.459 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Revenu total | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Revenu | 22.733 | 26.279 | 27.655 | 27.448 | 24.199 |
| Coût des recettes, total | 9.99 | 8.986 | 9.623 | 12.606 | 11.513 |
| Résultat brut | 12.743 | 17.293 | 18.032 | 14.842 | 12.686 |
| Total des frais d'exploitation | 31.291 | 33.072 | 29.308 | 45.361 | 78.685 |
| Total des frais de vente/Généraux/Admin | 19.981 | 18.578 | 17.424 | 17.396 | 17.358 |
| Recherche et développement | 0.856 | 1.71 | 1.064 | 3.697 | 3.726 |
| Depreciation / Amortization | 1.198 | 1.198 | 1.197 | 0.853 | 1.061 |
| Charges (revenus) inhabituelles | 0 | 2.6 | 10.809 | 45.027 | |
| Produits d'exploitation | -8.558 | -6.793 | -1.653 | -17.913 | -54.486 |
| Produits (charges) d'intérêts, nets Hors exploitation | 1.358 | 0.1 | 1.08 | -0.787 | -0.055 |
| Autres, nets | -0.128 | 0.999 | 1.468 | ||
| Résultat net avant impôts | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Résultat net après impôts | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Résultat net avant éléments extra | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Résultat net | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Revenu disponible pour les actionnaires ordinaires, hors éléments exceptionnels | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Bénéfice disponible pour les actionnaires ordinaires, y compris les éléments exceptionnels | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Résultat net dilué | -7.2 | -6.693 | -0.701 | -17.701 | -53.073 |
| Moyenne pondérée des actions diluées | 3.72678 | 3.1103 | 0.1259 | 0.08989 | 1.48449 |
| BPA dilué hors éléments extraordinaires | -1.93196 | -2.15188 | -5.56812 | -196.925 | -35.7516 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA dilué normalisé | -1.93196 | -1.31595 | -5.56812 | -76.6739 | -5.42003 |
| Other Operating Expenses, Total | -0.734 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 59.929 | 105.234 | 75.4226 | 15.4329 | 9.47029 |
| Espèces et placements à court terme | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Trésorerie et équivalents | 19.36 | 49.649 | 48.0817 | 11.0442 | 7.01253 |
| Investissements à court terme | |||||
| Total des créances, nettes | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Accounts Receivable - Trade, Net | 21.712 | 28.176 | 5.63272 | 1.74079 | 0.57878 |
| Total Inventory | 10.849 | 16.339 | 9.99944 | 1.44007 | 1.33897 |
| Prepaid Expenses | 7.375 | 9.78 | 5.71509 | 0.95778 | 0.44001 |
| Total Assets | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Property/Plant/Equipment, Total - Net | 6.296 | 8.703 | 0.89261 | 0.20373 | 0.21868 |
| Goodwill, Net | 0 | 65.802 | 28.0904 | 0 | |
| Intangibles, Net | 70.632 | 85.464 | 48.8546 | 19.0826 | 11.366 |
| Other Long Term Assets, Total | 0.766 | 0.465 | 0.03298 | 0.0022 | 0.00509 |
| Total Current Liabilities | 64.442 | 109.438 | 28.7634 | 5.37258 | 3.39478 |
| Payable/Accrued | 9.468 | 8.689 | 0.959 | ||
| Accrued Expenses | 35.946 | 49.485 | 11.1046 | 1.99724 | 0.72656 |
| Notes Payable/Short Term Debt | 3.813 | 7.934 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 4.132 | 7.407 | 4.87523 | 1.07807 | 0.54855 |
| Total Liabilities | 91.531 | 128.1 | 58.2778 | 27.6336 | 7.63559 |
| Total Long Term Debt | 14.279 | 0.18 | 0 | 0 | 0 |
| Other Liabilities, Total | 12.81 | 18.482 | 29.5145 | 22.261 | 4.24081 |
| Total Equity | 46.092 | 137.568 | 95.0153 | 7.08782 | 13.4245 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0.00036 | 0 |
| Common Stock | 0.004 | 0.003 | 0.00126 | 0.00175 | 0.00018 |
| Additional Paid-In Capital | 334.56 | 315.864 | 215.024 | 113.475 | 92.6819 |
| Retained Earnings (Accumulated Deficit) | -288.472 | -178.299 | -120.01 | -106.39 | -79.2576 |
| Total Liabilities & Shareholders’ Equity | 137.623 | 265.668 | 153.293 | 34.7214 | 21.0601 |
| Total Common Shares Outstanding | 1.92894 | 1.37452 | 0.62919 | 0.08769 | 0.00897 |
| Other Current Assets, Total | 0.633 | 1.29 | 5.9936 | 0.25 | 0.1 |
| Accounts Payable | 10.987 | 19.255 | 11.8246 | 2.29727 | 2.11967 |
| Property/Plant/Equipment, Total - Gross | 8.717 | 9.715 | 1.37661 | 0.59973 | 0.75868 |
| Accumulated Depreciation, Total | -2.421 | -1.012 | -0.484 | -0.396 | -0.54 |
| Total Preferred Shares Outstanding | 0 | 0 | 3.59498 | ||
| Current Port. of LT Debt/Capital Leases | 0.096 | 16.668 | 0 | ||
| Capital Lease Obligations | 0.084 | 0.18 | 0 | ||
| Long Term Debt | 14.195 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total de l'actif à court terme | 78.465 | 70.611 | 74.415 | 59.929 | 77.947 |
| Espèces et placements à court terme | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Trésorerie et équivalents | 19.179 | 19.501 | 23.811 | 19.36 | 27.613 |
| Total des créances, nettes | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Accounts Receivable - Trade, Net | 34.043 | 25.547 | 27.924 | 21.712 | 27.613 |
| Total Inventory | 13.637 | 12.95 | 12.871 | 10.849 | 13.891 |
| Prepaid Expenses | 10.429 | 11.989 | 9.024 | 7.375 | 7.942 |
| Other Current Assets, Total | 1.177 | 0.624 | 0.785 | 0.633 | 0.888 |
| Total Assets | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Property/Plant/Equipment, Total - Net | 4.395 | 5.019 | 5.648 | 6.296 | 7.04 |
| Property/Plant/Equipment, Total - Gross | 7.779 | 8.083 | 8.384 | 8.717 | 8.78 |
| Accumulated Depreciation, Total | -3.384 | -3.064 | -2.736 | -2.421 | -1.74 |
| Goodwill, Net | 0 | 8.637 | |||
| Intangibles, Net | 63.464 | 64.985 | 69.108 | 70.632 | 74.428 |
| Other Long Term Assets, Total | 0.892 | 0.821 | 0.829 | 0.766 | 0.774 |
| Total Current Liabilities | 85.416 | 67.15 | 73.204 | 64.442 | 80.36 |
| Accounts Payable | 14.673 | 10.58 | 14.667 | 10.987 | 11.13 |
| Payable/Accrued | 10.287 | 9.137 | 8.08 | 9.468 | 12.058 |
| Accrued Expenses | 40.55 | 33.326 | 34.603 | 35.946 | 47.873 |
| Notes Payable/Short Term Debt | 10.403 | 7.429 | 8.087 | 3.813 | 3.385 |
| Current Port. of LT Debt/Capital Leases | 3.305 | 0.09 | 0.925 | 0.096 | 0.1 |
| Other Current Liabilities, Total | 6.198 | 6.588 | 6.842 | 4.132 | 5.814 |
| Total Liabilities | 106.304 | 95.619 | 96.094 | 91.531 | 107.682 |
| Total Long Term Debt | 11.386 | 14.533 | 13.56 | 14.279 | 14.167 |
| Long Term Debt | 11.371 | 14.494 | 13.498 | 14.195 | 14.061 |
| Capital Lease Obligations | 0.015 | 0.039 | 0.062 | 0.084 | 0.106 |
| Other Liabilities, Total | 9.502 | 13.936 | 9.33 | 12.81 | 13.155 |
| Total Equity | 40.912 | 45.817 | 53.906 | 46.092 | 61.144 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.00038 | 0.00034 | 0.006 | 0.004 | 0.003 |
| Additional Paid-In Capital | 342.584 | 340.289 | 345.253 | 334.56 | 331.912 |
| Retained Earnings (Accumulated Deficit) | -301.672 | -294.472 | -291.353 | -288.472 | -270.771 |
| Total Liabilities & Shareholders’ Equity | 147.216 | 141.436 | 150 | 137.623 | 168.826 |
| Total Common Shares Outstanding | 3.77951 | 3.38315 | 3.12147 | 1.92894 | 1.6678 |
| Total Preferred Shares Outstanding | |||||
| Other Equity, Total | -0.00038 | -0.00034 |
- Annuel
- Trimestriel
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Revenu net/Ligne de départ | -110.173 | -58.289 | -13.6207 | -27.1319 | -10.1879 |
| Liquidités provenant des activités d'exploitation | -28.823 | -25.964 | -28.3739 | -13.8314 | -15.9403 |
| Liquidités provenant des activités d'exploitation | 10.251 | 9.201 | 6.24583 | 2.72707 | 2.59127 |
| Deferred Taxes | |||||
| Éléments non monétaires | 81.962 | 21.443 | -8.38913 | 10.7837 | -7.62492 |
| Variation du fonds de roulement | -10.863 | 1.681 | -12.6099 | -0.2102 | -0.71881 |
| Flux de trésorerie liés aux activités d'investissement | -3.248 | -2.782 | -5.65577 | -1.06199 | -0.48429 |
| Dépenses d'investissement | -2.341 | 0 | -0.05985 | -0.07471 | |
| Autres éléments de flux de trésorerie d'investissement, total | -3.248 | -0.441 | -5.65577 | -1.00214 | -0.40959 |
| Flux de trésorerie provenant des activités de financement | 1.53 | 30.314 | 71.0687 | 19.0751 | 22.6596 |
| Éléments de flux de trésorerie de financement | -4.942 | -10.996 | -5.40415 | -1.47996 | -2.75752 |
| Émission (remboursement) d'actions, nette | 11.694 | 45.051 | 92.7217 | 15.555 | 25.4171 |
| Émission (remboursement) de la dette, nette | -5.222 | -3.741 | -16.2488 | 5 | |
| Variation nette de la trésorerie | -30.541 | 1.568 | 37.0391 | 4.1817 | 6.23499 |
| Intérêts payés en espèces | 3.148 | 1.249 | 1.04028 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -14.594 | -7.394 | -2.881 | -110.173 | -92.472 |
| Cash From Operating Activities | -14.494 | -11.588 | -9.148 | -28.823 | -21.728 |
| Cash From Operating Activities | 6.699 | 4.505 | 2.328 | 10.251 | 8.005 |
| Non-Cash Items | 1.658 | 3.846 | 1.488 | 81.962 | 67.39 |
| Cash Interest Paid | 2.861 | 2.021 | 0.565 | 3.148 | 3.08 |
| Changes in Working Capital | -8.257 | -12.545 | -10.083 | -10.863 | -4.651 |
| Cash From Investing Activities | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Other Investing Cash Flow Items, Total | 0.038 | 0.037 | 0.042 | -3.248 | -3.207 |
| Cash From Financing Activities | 14.275 | 11.692 | 13.557 | 1.53 | 2.647 |
| Financing Cash Flow Items | -5.254 | -3.497 | -1.107 | -4.942 | -4.429 |
| Issuance (Retirement) of Stock, Net | 13.012 | 11.573 | 10.416 | 11.694 | 12.7 |
| Issuance (Retirement) of Debt, Net | 6.517 | 3.616 | 4.248 | -5.222 | -5.624 |
| Net Change in Cash | -0.181 | 0.141 | 4.451 | -30.541 | -22.288 |
| Capital Expenditures |
| Nom de l'investisseur | Catégorie de l'investisseur | Pourcentage de l'encours | Actions détenues | Changement d'actions | Date d'avoirs | Taux du chiffre d'affaires |
|---|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | Hedge Fund | 7.1847 | 271595 | 0 | 2023-05-26 | LOW |
| Alyeska Investment Group, L.P. | Hedge Fund | 1.984 | 75000 | 0 | 2023-03-31 | LOW |
| Brooke (Christopher) | Individual Investor | 1.5438 | 58357 | 58357 | 2022-11-15 | |
| Disbrow (Joshua R.) | Individual Investor | 1.5235 | 57591 | -3 | 2023-03-24 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.3127 | 49623 | -57416 | 2023-03-31 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.2503 | 47263 | 4379 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 0.6365 | 24059 | -1 | 2023-03-31 | LOW |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 0.5962 | 22537 | 2640 | 2023-03-31 | MED |
| Commonwealth Financial Network | Investment Advisor | 0.4137 | 15637 | 159 | 2023-03-31 | LOW |
| PGIM Quantitative Solutions LLC | Investment Advisor | 0.375 | 14176 | 5198 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.3185 | 12039 | -2 | 2023-03-31 | LOW |
| Oki (Mark K) | Individual Investor | 0.2513 | 9500 | 0 | 2023-03-24 | LOW |
| Pyszczymuka (Greg) | Individual Investor | 0.2408 | 9103 | 5000 | 2022-12-19 | |
| Cantrell (Gary V.) | Individual Investor | 0.217 | 8204 | -2000 | 2022-12-21 | |
| Dockery (Carl C) | Individual Investor | 0.2157 | 8152 | -2 | 2023-03-24 | LOW |
| Liu (Vivian H) | Individual Investor | 0.1805 | 6825 | 0 | 2023-03-24 | HIGH |
| Ronald Blue Trust, Inc. | Investment Advisor | 0.1476 | 5579 | 5300 | 2023-03-31 | LOW |
| UBS Financial Services, Inc. | Investment Advisor | 0.1395 | 5273 | 5012 | 2023-03-31 | LOW |
| Tower Research Capital LLC | Hedge Fund | 0.0457 | 1726 | 113 | 2023-03-31 | HIGH |
| Morgan Stanley & Co. LLC | Research Firm | 0.0228 | 861 | 0 | 2023-03-31 | MED |
Pourquoi choisir capital.com? Nos chiffres parlent d'eux-mêmes.
Capital.com Group535K+
Tradeurs
87K+
Clients actifs par mois
$113M+
Volume d'investissement par mois
$64M+
Retrait par mois
Trading calculator
Calculez votre P&L hypothétique si vous aviez ouvert une transaction CFD à une certaine date (sélectionnez une date) et l'aviez fermée à une autre date (sélectionnez une date).
Trade commission
0
- 1:1
Effet de levier
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Ouverture
Clôture
Short Long
Aytu BioScience, Inc. Company profile
À propos de Aytu BioScience, Inc.
Aytu Biopharma, Inc, anciennement Aytu BioScience, Inc, est une société pharmaceutique spécialisée. La société commercialise un portefeuille de produits de prescription destinés aux marchés des soins primaires et de la pédiatrie. Les principaux produits de prescription de la société traitent le trouble déficitaire de l'attention avec hyperactivité (TDAH) et d'autres conditions pédiatriques courantes. Elle commercialise les produits TDAH Adzenys XR-ODT (amphétamine), comprimés à dissolution orale à libération prolongée, Cotempla XR-ODT (méthylphénidate), comprimés à dissolution orale à libération prolongée, et Adzenys-ER (amphétamine), suspension orale à libération prolongée. Les autres produits pédiatriques de la société comprennent Karbinal ER (maléate de carbinoxamine), une suspension de carbinoxamine (antihistaminique) à libération prolongée indiquée pour traiter de nombreuses affections allergiques, et Poly-Vi-Flor et Tri-Vi-Flor, deux gammes complémentaires de vitamines sur ordonnance à base de fluorure contenant des combinaisons de fluorure et de vitamines dans des formulations destinées aux nourrissons et aux enfants présentant une carence en fluorure.
| Industry: | Pharmaceuticals (NEC) |
373 Inverness Pkwy Ste 206
80112
Compte de résultat
- Annual
- Quarterly
Les gens regardent aussi
Êtes-vous toujours à la recherche d'un broker de confiance?
Rejoignez les plus de 535 000 traders du monde entier qui ont choisi de trader avec Capital.com